Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Eur J Cancer ; 200: 113560, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38306841

ABSTRACT

BACKGROUND: Neoadjuvant chemotherapy (NACT) with TPF (docetaxel, cisplatin, and 5FU) is one of the treatment options in very locally advanced oral cancer with a survival advantage over PF (cisplatin and 5FU). TP (docetaxel and cisplatin) has shown promising results with a lower rate of adverse events but has never been compared to TPF. METHODS: In this phase 3 randomized superiority study, adult patients with borderline resectable locally advanced oral cancers were randomized in a 1:1 fashion to either TP or TPF. After the administration of 2 cycles, patients were evaluated in a multidisciplinary clinic and further treatment was planned. The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) and adverse events. RESULTS: 495 patients were randomized in this study, 248 patients in TP arm and 247 in TPF arm. The 5-year OS was 18.5% (95% CI 13.8-23.7) and 23.9% (95% CI 18.1-30.1) in TP and TPF arms, respectively (Hazard ratio 0.778; 95% CI 0.637-0.952; P = 0.015). Following NACT, 43.8% were deemed resectable, but 34.5% underwent surgery. The 5-year OS was 50.7% (95% CI 41.5-59.1) and 5% (95%CI 2.9-8.1), respectively, in the surgically resected versus unresected cohort post NACT (P < 0.0001). Grade 3 or above adverse events were seen in 97 (39.1%) and 179 (72.5%) patients in the TP and TPF arms, respectively (P < 0.0001). CONCLUSION: NACT with TPF has a survival benefit over TP in borderline resectable oral cancers, with an increase in toxicity which is manageable. Patients who undergo surgery achieve a relatively good, sustained survival.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Mouth Neoplasms , Adult , Humans , Docetaxel/therapeutic use , Platinum/therapeutic use , Cisplatin , Neoadjuvant Therapy , Fluorouracil , Taxoids/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Mouth Neoplasms/drug therapy , Mouth Neoplasms/surgery , Induction Chemotherapy/methods , Head and Neck Neoplasms/drug therapy
2.
Angew Chem Int Ed Engl ; 62(50): e202314451, 2023 Dec 11.
Article in English | MEDLINE | ID: mdl-37874893

ABSTRACT

In recent times, heterogenization of homogeneous molecular catalysts onto various porous solid support structures has attracted significant research focus as a method for combining the advantages of both homogeneous as well as heterogeneous catalysis. The design of highly efficient, structurally robust and reusable heterogenized single-site catalysts for the CO2 hydrogenation reaction is a critical challenge that needs to be accomplished to implement a sustainable and practical CO2 -looped renewable energy cycle. This study demonstrated a heterogenized catalyst [Ir-HCP-(B/TPM)] containing a molecular Ir-abnormal N-heterocyclic carbene (Ir-aNHC) catalyst self-supported by hierarchical porous hyper-crosslinked polymer (HCP), in catalytic hydrogenation of CO2 to inorganic formate (HCO2 - ) salt that is a prospective candidate for direct formate fuel cells (DFFC). By employing this unique and first approach of utilizing a directly knitted HCP-based organometallic single-site catalyst for CO2 -to-HCO2 - in aqueous medium, extremely high activity with a single-run turnover number (TON) up to 50816 was achieved which is the highest so far considering all the heterogeneous catalysts for this reaction in water. Additionally, the catalyst featured excellent reusability furnishing a cumulative TON of 285400 in 10 cycles with just 1.6 % loss in activity per cycle. Overall, the new catalyst displayed attributes that are important for developing tangible catalysts for practical applications.

3.
Comput Mol Biosci ; 13(2): 21-34, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37538932

ABSTRACT

Triple Negative Breast Cancer (TNBC) is a malignant form of cancer with very high mortality and morbidity. Epithelial to Mesenchymal Transition (EMT) is the most common pathophysiological change observed in cancer cells of epithelial origin that promotes metastasis, drug resistance and cancer stem cell formation. Since the information regarding differential gene expression in TNBC cells and cell signaling events leading to EMT is limited, this investigation was done by comparing transcriptomic data generated by RNA isolation and sequencing of a EMT model TNBC cell line in comparison to regular TNBC cells. RNA sequencing and Ingenuity Pathway Software Analysis (IPA) of the transcriptomic data revealed several upregulated and downregulated gene expressions along with novel core canonical pathways including Sirtuin signaling, Oxidative Phosphorylation and Mitochondrial dysfunction events involved in EMT changes of the TNBC cells.

4.
Chem Rec ; 22(12): e202200165, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36002341

ABSTRACT

Molecular assembly induced by metal-terpyridine-based coordinative interactions has become an emergent research topic due to its ease of synthesis and diverse applications. This article highlights recent significant developments in the metal-terpyridine-based supramolecular architectures. At first, the design aspect of the molecular building blocks has been described, followed by elaboration on how the ligand backbone plays an important role for achieving different dimensionalities of the resulting assemblies which exhibit a wide range of potential applications. After that, we discussed different synthetic approaches for constructing these assemblies, and finally, we focused on their significant developments in three specific areas, viz., electrochromic materials, catalysis and a new application in wastewater treatment. In the field of electrochromic materials, these assemblies made important advancements in various aspects like sub-second switching time (<1 s), low switching voltage (<1 V), increased switching stability (>10000 cycles), tuning of multiple colors by using multimetallic systems, fabrication of charge storing electrochromic devices, utilizing and storing solar energy etc. Similarly, the catalysis field witnessed application of the metal-terpyridine assemblies in C-H monohalogenation, heterogeneous Suzuki-Miyaura coupling, photocatalysis, reduction of carbon dioxide, etc. Finally, the environmental application of these coordination assemblies includes capturing Cr(VI) from waste water efficiently with high capture capacity, good recyclability, wide pH independency etc.

5.
Indian J Surg Oncol ; 13(1): 61-67, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35462671

ABSTRACT

There is a paucity of evidence of the impact of sorafenib on MCT and it is the preferred therapy used in India. We decided to do an audit of all patients of MCT who were referred to us for systemic therapy. The objective of this exercise was to identify the treatment pattern, outcomes, and adverse events with therapy in MCT. Baseline demographics (age, gender, ECOG PS, comorbidities, habits), tumor details (site of metastasis), previous treatment details, clinical features at metastasis (symptomatic or asymptomatic), the pattern of treatment, adverse events (CTCAE version 4.02), date of progression, date of death and status, and follow-up were extracted from the rare tumor database and electronic medical records. Out of 75 patients referred for therapy for MCT, 47 (62.7%) patients were considered for immediate tyrosine kinase inhibitors as they had symptomatic status and 28 (37.3%) patients were kept on observation due to the asymptomatic nature of the disease. Out of the 28 patients, 15 (53.6%, n = 28) patients were subsequently started on TKI while in 13 (46.4%, n = 28) patients observation was continued. In the overall cohort, the median PFS was 18.9 months (95% CI 11.9-29.9) and OS was 26.6 months (95% CI 14.4-39.0). Among variables tested, only female gender had an impact on PFS (hazard ratio = 0.364 95% CI 0.148-0.895; P = 0.028) and the absence of lung metastasis had a positive impact on OS (hazard ratio = 0.443 95% CI 0.207-0.95; P = 0.037). Most commonly used TKI was sorafenib (n = 61) and sunitinib in 1 patient. The most common adverse events with TKI were palmo-plantar dysesthesia (50, 80.6%) and oral mucositis (25, 40.2%). The strategy of treating symptomatic MCT and observing in asymptomatic MCT is associated with reasonable PFS and OS. Sorafenib is the most commonly used TKI in our setup and provides similar outcomes as globally.

6.
Indian J Surg Oncol ; 13(1): 81-86, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35462674

ABSTRACT

The real-world patterns of TKI use in differentiated thyroid cancer (DTC) are largely governed by the accessibility and financial feasibility of the patient with more sorafenib use compared to lenvatinib. There are limited data available on the toxicity profile, safety and tolerance of sorafenib and lenvatinib in DTC. Hence, we audited our practice on DTC. This is a retrospective single-centre analysis of patients with DTC who were referred to the Department of Medical Oncology for systemic therapy. Baseline demographics (age, sex, ECOG PS, comorbidities, substance use), tumour details (site of metastasis), previous treatment details, clinical features at metastasis (symptoms), the pattern of treatment, adverse events and outcomes including progression and death were extracted. There were 67 patients with DTC referred for systemic therapy; the median age was 56 (33-81) with a male preponderance (55.6%). The most common reason to start TKI therapy was radioactive iodine (RAI) cumulative dose > 600 milliCurie, followed by low iodine uptake in the RAI low-dose scan done at progression. The most common TKI used in the first line was sorafenib in 56 (83.6%) patients followed by lenvatinib in 9 (13.4%) patients. Papillary thyroid carcinoma was the most common histology (51, 76.1%), and the rest were follicular carcinoma (16, 23.9%). With a median follow-up of 36 months, the median PFS was 13.2 months (95% CI 10.4-16.0). The median OS was 18.8 months (95% CI 10.0-27.6). Among variables tested, no factors had a significant impact on the PFS or OS. The most common adverse events were hand-foot syndrome (54, 80.5%), diarrhoea (23, 33.3%) and transaminitis (24, 34.4%). The pattern of care of patients with RAI-refractory DTC is TKI therapy, especially sorafenib and lenvatinib in the real-world settings with comparable efficacy and safety profile compared to international literature.

7.
Ecancermedicalscience ; 16: 1460, 2022.
Article in English | MEDLINE | ID: mdl-36819802

ABSTRACT

Background: The data regarding the use of neoadjuvant chemotherapy in technically unresectable head and neck cancer (HNC) is limited and real-world studies are needed to look for the efficacy and toxicities of this approach. Patients and methods: This is a retrospective study conducted in the Medical Oncology department of our hospital. All technically unresectable HNC patients who underwent neoadjuvant chemotherapy between May 2018 and May 2020 were included in this analysis. Patients received three-drug regimen docetaxel, cisplatin and 5-fluorouracil (DCF) regimen, two-drug regimens included docetaxel + cisplatin, paclitaxel + carboplatin both weekly and 3-weekly. The resectability assessment was done clinically and radiologically after completing three neoadjuvant cycles. Overall survival was calculated from the first day of chemotherapy to the date of last follow-up or date of death. Results: A total of 119 patients received neoadjuvant chemotherapy during the specified time. Response assessment showed partial response in 41.9% of patients with three-drug regimens and 37.5% of patients with other regimens. Out of 119 patients, 56 (47%) patients were offered radical intent therapy. Resectability was achieved in 32.3% of three-drug regimen patients and 26.1% of other patients. Surgery was feasible in 33 (27.7%) patients, and postoperative radiotherapy and concurrent chemotherapy were done in 30 patients (25.2%), and surgery with only postoperative radiotherapy was done in 3 patients (2.5%). Radical chemoradiotherapy was done in 23 patients (19.3%). The estimated median survival for patients who could undergo surgery was 18 months [95% confidence interval (CI), 14.9-21.0], and nonsurgical patients were 9 months (95% CI, 7.3-10.6) (p = 0.0001). Conclusion: Our study shows that neoadjuvant chemotherapy in technically unresectable HNC patients can make the disease resectable in around one-third of the patients. The patients who could undergo surgery after neoadjuvant chemotherapy had significantly improved survival as compared to those who could not.

8.
Chem Commun (Camb) ; 57(79): 10182-10185, 2021 Oct 05.
Article in English | MEDLINE | ID: mdl-34523654

ABSTRACT

Three-dimensionally propagated imidazolium-containing mesoporous coordination polymer and organic polymer-based platforms were successfully exploited to develop single-site heterogenized Pd-NHC catalysts for oxidative arene/heteroarene C-H functionalization reactions. The catalysts were efficient in directed arene halogenation, and nondirected arene and heteroarene arylation reactions. High catalytic activity, excellent heterogeneity and recyclability were offered by these systems making them promising candidates in the area of heterogeneous C-H functionalization, where efficient catalysts are still scarce.

9.
Chem Asian J ; 14(24): 4774-4779, 2019 Dec 13.
Article in English | MEDLINE | ID: mdl-31560812

ABSTRACT

Presented herein is a set of bimetallic and trimetallic "coordination booster-catalyst" assemblies in which the coordination complexes [RuII (terpy)2 ] and [OsII (terpy)2 ] acted as boosters for enhancement of the catalytic activity of [RuII (NHC)(para-cymene)]-based catalytic site. The boosters accelerated the oxidative loss of para-cymene from the catalytic site to generate the active catalyst during the oxidation of alkenes and alkynes into corresponding aldehydes, ketones and diketones. It was found that the boosting efficiency of the [OsII (terpy)2 ] units was considerably higher than its congener [RuII (terpy)2 ] unit in these assemblies. Mechanistic studies were conducted to understand this unique improvement.

10.
Pediatr Blood Cancer ; 66(9): e27877, 2019 09.
Article in English | MEDLINE | ID: mdl-31207015

ABSTRACT

BACKGROUND: The management of osteosarcoma is challenging especially in lower-income and middle-income countries, and there is an unmet need to evolve efficient and sustainable chemotherapy regimens. METHODS: We compared the outcomes in nonmetastatic osteosarcoma patients treated with three sequential non-high-dose methotrexate-based combination chemotherapy protocols at a single tertiary care center over two decades. The first protocol, OGS-99, involved dose-intense, alternating dyads of three drugs: doxorubicin (Dox), cisplatin (CDDP), and ifosfamide (Ifo). The second protocol, OGS-99 enhanced, included OGS-99 drugs with etoposide and enhanced supportive care. The OGS-12 protocol involved dose-dense administration of eight sequential dyads of Dox, CDDP and Ifo, universal growth factor prophylaxis and targeted nutritional support. Event-free survival (EFS), overall survival (OS), and toxicity were reported using a retrospective chart review in the OGS-99 and OGS-99 enhanced protocols and prospectively in the OGS-12 protocol. RESULTS: A total of 41, 94, and 385 treatment-naïve, consecutive, nonmetastatic patients with extremity osteosarcoma were treated with the OGS-99 (2000-2005), OGS-99 enhanced (2010), and OGS-12 (2011-2016), respectively. At a median follow-up of 19, 86, and 39 months, the five-year EFS rates were 38%, 50%, and 62% in the OGS-99, OGS-99 enhanced, and OGS-12, respectively. The corresponding rates of five-year OS were nonevaluable, 60% and 77%, respectively, with acceptable rates of grade 3-4 toxicities: febrile neutropenia (40%), thrombocytopenia (36%), anemia (51%), and 1% deaths related to toxicity. CONCLUSIONS: Sequential selection of an intelligent, dose-dense chemotherapy regimen together with enhanced supportive care resulted in marked improvement in outcomes of nonmetastatic osteosarcoma and this "small steps-big changes" model deserves wider recognition and usage.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bone Neoplasms , Osteosarcoma , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Neoplasms/drug therapy , Bone Neoplasms/mortality , Child , Cisplatin/administration & dosage , Cisplatin/adverse effects , Disease-Free Survival , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Etoposide/administration & dosage , Etoposide/adverse effects , Female , Humans , Ifosfamide/administration & dosage , Ifosfamide/adverse effects , India , Male , Middle Aged , Osteosarcoma/drug therapy , Osteosarcoma/mortality , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...